Uncategorized

AstraZeneca may have provided incomplete efficacy data from latest COVID-19 trial: NIAID By Reuters

[ad_1]

2/2

© Reuters. Portugal resumes AstraZeneca vaccination after temporary suspension

2/2

(Reuters) – British drugmaker AstraZeneca (NASDAQ:) Plc may have provided an incomplete view of efficacy data on its COVID-19 vaccine from a large scale U.S. trial, the U.S. National Institute of Allergy and Infectious Diseases (NIAID) said on Tuesday, in a fresh setback to the shot.

AstraZeneca said a day earlier that its COVID-19 vaccine developed with Oxford University was 79% effective in preventing symptomatic illness in a large trial in the United States, Chile and Peru.

“The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data,” the U.S. agency said, referring to the independent Data Safety Monitoring Board (DSMB).

“We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible.”

The request cast doubts over the company’s plan to seek U.S. emergency use authorization for the vaccine in the coming weeks.

Authorization and guidelines for use of the vaccine in the United States will be determined by the Food and Drug Administration and Centers for Disease Control and Prevention after thorough review of the data by independent advisory committees, said the NIAID, part of the National Institutes of Health.

AstraZeneca did not immediately respond to a Reuters request for comment.

Hailed as a milestone in the fight against the COVID-19 pandemic when it emerged as a vaccine contender last year, the AstraZeneca shot has been dogged by doubts over its efficacy, dosing regimen and possible side effects.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.



[ad_2]

Read More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button